<div id="readability-page-1"><div><p>WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how quality and compliance feed into its equity story.</p> <p>See our latest analysis for WuXi Biologics (Cayman).</p> <p>The ISO 13485:2016 win comes as the share price trades at HK$37.18, with a 1 month share price return of 6.41% and a year to date share price return of 14.26%. Over a longer horizon, the 1 year total shareholder return of 81.37% contrasts with a 3 year total shareholder return decline of 28.71% and a 5 year total shareholder return decline of 66.26%, suggesting recent momentum is building off a weaker multi year record.</p> <p>If quality and compliance driven stories like WuXi Biologics interest you, it may be worth scanning a wider set of healthcare names using our screener for 125 healthcare AI stocks</p> <p>With WuXi Biologics trading at HK$37.18, an indicated intrinsic value gap of 38% and a 24% discount to the average analyst target, the key question is whether this is genuine mispricing or if markets are already incorporating expectations about future growth.</p> <h2>Most Popular Narrative: 18% Undervalued</h2> <p>At HK$37.18, the most followed narrative sees WuXi Biologics trading below an estimated fair value of HK$45.08, putting the focus firmly on whether its growth and margin profile can justify that gap.</p> <blockquote> <p><em>The accelerated ramp in ADC (antibody-drug conjugates) and bispecific/multi-specific project wins, now making up over 40% of WuXi Biologics' portfolio and driving new, high-complexity business, positions the company as the partner of choice in these fast-growing biologics segments. This supports sustained backlog growth and provides strong visibility into higher late-stage and manufacturing revenues over the next 3-5 years.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>Want to see what revenue mix shift, margin assumptions, and future earnings multiple sit behind that HK$45.08 figure? The fair value hinges on a detailed blend of forecast growth, profitability, and discounting that is not obvious from the current share price alone.</p> <p><strong>Result: Fair Value of HK$45.08 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, your thesis still hinges on geopolitical risk around China based CDMOs and high exposure to North America, where any regulatory shift or client loss could quickly change the story.</p> <p>Find out about the key risks to this WuXi Biologics (Cayman) narrative.</p> <h2>Next Steps</h2> <p>If this combination of optimism and risk gives you mixed feelings, consider acting promptly. Review the numbers yourself and weigh what matters most to you using 4 key rewards</p> <h2>Looking for more investment ideas?</h2> <p>If WuXi Biologics has sharpened your focus, do not stop here. Use the screener to widen your watchlist and spot opportunities you might otherwise miss.</p> <ul> <li>Spot potential mispriced opportunities by scanning our set of companies trading below fair value using the 227 high quality undervalued stocks.</li> <li>Strengthen your portfolio’s foundation by filtering for businesses with robust finances through the solid balance sheet and fundamentals stocks screener (391 results).</li> <li>Seek under the radar opportunities that still show quality fundamentals by running the screener containing 575 high quality undiscovered gems.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if WuXi Biologics (Cayman) might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

WXXWY

02269

<p>WuXi Biologics (SEHK:2269) has secured ISO 13485:2016 certification for its medical device quality management system, highlighting its commitment to quality and compliance. The company's share price is currently HK$37.18, with a 1-month return of 6.41% and a year-to-date return of 14.26%. Analysts suggest the stock is undervalued, with a fair value estimate of HK$45.08, indicating a potential 38% intrinsic value gap. The company is positioned for growth in the biologics sector, but faces geopolitical risks that could impact its performance.</p>

A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification